Allergy Therapeutics plc (AGY) · 2026-07-29
Allergy Therapeutics expects FY2026 revenue of GBP59.9m, up 9% from GBP55.0m, with growth of approximately 5% at constant currency. H2 revenue is expected to rise over 12% to GBP23.6m, and the group expects year-on-year double-digit revenue growth in FY2027.
Allergy Therapeutics plc (AGY) · 2026-07-28
Allergy Therapeutics plc appointed Helge Weiner-Trapness as Executive Chairman on 28 July 2026, replacing Peter Jensen OBE after more than 15 years with the group. Weiner-Trapness has been Chief Strategy Officer and an Executive Director since January 2026, while Jensen will remain a Non-Executive Director until the next Annual General Meeting.
Allergy Therapeutics plc (AGY) · 2026-06-12
Allergy Therapeutics is presenting 15 research abstracts at the EAACI Congress 2026. Data confirms the Phase I/IIa PROTECT trial for VLP Peanut met its primary endpoint and achieved clinical proof of concept. Blinded Phase III paediatric safety data for Grass MATA MPL showed low discontinuation rates.